RVPH (Reviva Pharmaceuticals Holdings) Other Current Receivables: $0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

RVPH Reviva Pharmaceuticals Holdings Inc RVPH
22 GF Score
Price $0.55
! 1 Warning Sign
View Full Analysis

What is Reviva Pharmaceuticals Holdings Other Current Receivables?

Reviva Pharmaceuticals Holdings RVPH -7.08% 22 Other Current Receivables is $0.00 Mil as of Mar. 2026. GuruFocus rates RVPH with a GF Score™ of 22/100. The stock has 1 warning sign investors should review.

Reviva Pharmaceuticals Holdings's Other Current Receivables for the quarter that ended in Mar. 2026 was $0.00 Mil.

Reviva Pharmaceuticals Holdings Other Current Receivables Related Terms

Reviva Pharmaceuticals Holdings Other Current Receivables Historical Data

* Premium members only.

The historical data trend for Reviva Pharmaceuticals Holdings's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Reviva Pharmaceuticals Holdings Other Current Receivables Chart

Reviva Pharmaceuticals Holdings Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Receivables
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Reviva Pharmaceuticals Holdings Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
RVPH
22GF Score
Reviva Pharmaceuticals Holdings Inc RVPH
Other Current Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Reviva Pharmaceuticals Holdings Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

What does a Other Current Receivables of $0.00 Mil mean?
Reviva Pharmaceuticals Holdings (RVPH) has a Other Current Receivables of $0.00 Mil as of Mar. 2026. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Reviva Pharmaceuticals Holdings and its competitors.
Is Reviva Pharmaceuticals Holdings' Other Current Receivables too high?
Reviva Pharmaceuticals Holdings' current Other Current Receivables is $0.00 Mil. Overall, Reviva Pharmaceuticals Holdings has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Reviva Pharmaceuticals Holdings' Other Current Receivables compare to AIM and BOLT?
Reviva Pharmaceuticals Holdings' Other Current Receivables of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Receivables for a Biotechnology company?
A good Other Current Receivables depends on the Biotechnology industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Receivables mean?
A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Reviva Pharmaceuticals Holdings and its competitors. Reviva Pharmaceuticals Holdings's current Other Current Receivables is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Reviva Pharmaceuticals Holdings stock overvalued right now?
Reviva Pharmaceuticals Holdings (RVPH) has a current Other Current Receivables of $0.00 Mil. The current Other Current Receivables is $0.00 Mil. Reviva Pharmaceuticals Holdings' overall GF Score™ is 22/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Receivables calculated?
Other Current Receivables is calculated from a company's financial statements. For Reviva Pharmaceuticals Holdings (RVPH), the current Other Current Receivables is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Reviva Pharmaceuticals Holdings Business Description

Address 10080 North Wolfe Road, Suite SW3-200, Cupertino, CA, USA, 95014
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063), which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, and Parkinson's disease psychosis, and its other drug candidate is RP1208.
22GF Score

Get the complete analysis for RVPH

Other Current Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.55
Price